ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0561

Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort

Annie Brink1, Elisabeth Mogard2, Elisabet Lindqvist2, Jonas Sagard2, Johan Karlsson Wallman1 and Tor Olofsson2, 1Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, 2Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden

Meeting: ACR Convergence 2024

Keywords: Biologicals, fibromyalgia, Patient reported outcomes, spondyloarthritis, work

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: A growing arsenal of biologic/targeted synthetic DMARDs often makes inflammation control an attainable target in axial spondyloarthritis (axSpA). Yet, many patients keep suffering from chronic, generalized pain − frequently in its most severe form fibromyalgia (FM) − whereas structured studies of its impact in axSpA are scant. Here, we aimed to estimate the prevalence of thoroughly classified FM in axSpA, explore potential drivers of FM, and study the impact of FM on various disease/health measures, work ability and treatments.

Methods: We included 243 well-characterized axSpA patients from the population-based SPARTAKUS cohort, comprising individuals with both non-radiographic (nr-axSpA; n=78) and radiographic (r-axSpA; n=165) disease. FM was assessed by the 1990 ACR classification criteria. Moreover, patients were evaluated for tender/swollen joints, inflammatory markers, specific axSpA measures (disease activity, physical function, mobility), general patient-reported outcomes, lifestyle factors (BMI, smoking, alcohol use, physical activity), work ability, and treatment history. Potential drivers of FM were cross-sectionally analyzed by logistic regression (FM dependent variable), and variables rather hypothesized to be effects of FM by linear/logistic regression (FM independent variable); crude and adjusted, and with bootstrapped 95% confidence intervals in case of skewness.

Results: Among the axSpA patients, the proportion of women/mean age/mean symptom duration was 47%/51y/25y. The overall FM prevalence was 9%, with a higher share in female than male patients: 17% vs 2% (crude OR 12.9, 95%CI 2.94–56.9; Figure 1). In crude analysis, FM was also more frequent in patients with higher BMI (OR 1.15, 95%CI 1.05–1.26 per unit increase), and in HLA-B27 negative patients (OR 2.87 95%CI 1.03–8.04 vs positive). Multivariably (including significant variables from crude analysis), only sex and BMI remained significant. No relation to FM status was found for age, symptom duration, axSpA subtype, or CRP level. Regarding the impact of FM, its presence was associated (crude and age/sex adjusted; Table 1) with more tender (but not swollen) joints, worse axSpA disease activity measures (ASDAS-CRP, BASDAI), lower well-being and quality of life (Visual Analogue Scale [VAS] global/pain/fatigue, EQ-5D utility), more functional limitations (BASFI), and lower vital capacity. AxSpA patients with FM also reported more activity impairment and less employment, and were more likely to have received ≥1 DMARD (any) and ≥3 biological DMARDs (Figure 2).

Conclusion: FM is a common comorbidity in axSpA and markedly more frequent in female patients and in those with higher BMI. It is linked to higher disease activity measures, lower well-being and less employment, but not to more objective signs of inflammation. Moreover, axSpA patients with FM have more often tried multiple biological DMARDs, which may reflect difficulties in evaluating axSpA disease activity in the presence of FM. The results underscore a strong negative health impact of comorbid FM and highlight the need for closer monitoring, as well as proper pain-specific pharmacological and non-pharmacological treatments.

Supporting image 1

Figure 1. Frequencies of fibromyalgia in axSpA patients, stratified according to different background characteristics, axSpA phenotypes and lifestyle factors; with comparisons between strata of each variable by univariate logistic regression, and P values <0.05 considered significant. High-risk alcohol use: weekly consumption of >14 standard units (men) and >9 standard units (women). Physical inactivity: less than 150 minutes of exercise (of moderate intensity) per week (cut-offs for alcohol use/physical activity according to recommendations from the Swedish National Board of Health and Welfare). Musculoskeletal and extra-musculoskeletal manifestations are categorized as yes (ever) or no (never). AxSpA, axial spondyloarthritis; r-axSpA, radiographic axSpA; nr-axSpA, non-radiographic axSpA.

Supporting image 2

Supporting image 3

Figure 2. Associations between comorbid fibromyalgia and number of DMARDs (ever) among patients with axial spondyloarthritis (axSpA), from univariate logistic regression. *Significant association also after adjustment for age and sex. csDMARDs, conventional synthetic DMARDs; bDMARDs, biologic DMARDs.


Disclosures: A. Brink: None; E. Mogard: AbbVie/Abbott, 12, Development of educational material, Novartis, 12, Development and presentation of educational material; E. Lindqvist: None; J. Sagard: None; J. Karlsson Wallman: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Eli Lilly, 5, Novartis, 5, Pfizer, 5; T. Olofsson: MSD, 12, Co-author of paper without financial support, UCB, 12, Co-author of paper without financial support.

To cite this abstract in AMA style:

Brink A, Mogard E, Lindqvist E, Sagard J, Karlsson Wallman J, Olofsson T. Axial Spondyloarthritis Patients with Comorbid Fibromyalgia Feel Worse, Work Less and More Often Try Multiple Biological DMARDs − Results from a Population-Based Cohort [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/axial-spondyloarthritis-patients-with-comorbid-fibromyalgia-feel-worse-work-less-and-more-often-try-multiple-biological-dmards-%e2%88%92-results-from-a-population-based-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/axial-spondyloarthritis-patients-with-comorbid-fibromyalgia-feel-worse-work-less-and-more-often-try-multiple-biological-dmards-%e2%88%92-results-from-a-population-based-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology